<DOC>
	<DOCNO>NCT00346892</DOCNO>
	<brief_summary>`` The primary objective study demonstrate co-administering HRV vaccine OPV induce significant decrease poliovirus immune response one month third dose combine vaccine . The primary objective reach one month third dose polio vaccine , upper limit 95 % CI difference Seroprotection rate group B C pool ( minus ) group A 10 % polio serotype . ''</brief_summary>
	<brief_title>To Evaluate 2 Doses GSK Biologicals ' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV IPV</brief_title>
	<detailed_description>The study three group : Group A : HRV + OPV + DTPa/Hib ; Group B : HRV + placebo OPV + DTPa-IPV/Hib ; Group C : HRV Placebo + OPV + DTPa/Hib . Two cohort : Subjects enrol 2002 RV season receive two dos HRV placebo approximately 6 10 week age ( first cohort ) subject enrolled 2002 RV season receive vaccination approximately 10 14 week age ( second cohort ) . Routine EPI vaccination administer concomitantly study vaccine .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy infant 5 10 week age first study vaccination ( 2002 RV season ) confirm negative HIV status subject 's mother pregnancy thereafter . Exclusion criterion : History allergic disease , confirm suspected immunosuppressive immunodeficient condition , clinically significant history chronic gastrointestinal disease serious medical condition determine investigator receive treatment prohibit protocol .</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis rotavirus</keyword>
</DOC>